A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
NCT04458857
Recruiting
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of EM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of EM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical ou... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
11/29/2023
Locations: Teva Investigational Site 14281, Little Rock, Arkansas +88 locations
Conditions: Migraine
Register for Updates
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
NCT03832998
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric subjects with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
11/29/2023
Locations: Paradigm Clinical Research - La Mesa, La Mesa, California +94 locations
Conditions: Migraine
Register for Updates
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age
NCT04464707
Recruiting
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical out... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
11/29/2023
Locations: Teva Investigational Site 14281, Little Rock, Arkansas +89 locations
Conditions: Migraine
Register for Updates
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
NCT06051604
Recruiting
This is a prospective, double-blind, sham-controlled, randomized two-part clinical trial with an adaptive design. This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home setting. This study will be conducted in two parts. The first part of this study aims to determine the most effective dose of Mi-Helper and the second part aims to evaluate the efficacy, safety, and tolerability o... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/29/2023
Locations: ObvioHealth, New York, New York
Conditions: Episodic Migraine, Migraine With Aura, Migraine Without Aura, Migraine
Register for Updates
Emgality for Migraine in Breastmilk
NCT06085144
Recruiting
The goal of this project is to evaluate galcanezumab transfer into maternal breastmilk, and to evaluate infant (growth, development, constipation, colic, infections) and maternal (headache) outcomes for dyads in which the mother was treated with galcanezumab and to compare outcomes for infants who were or were not breastfed after maternal treatment. In this prospective observational study, the study team proposes to prospectively collect serial milk samples from 30 adult women who are treated w... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
11/28/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Migraine
Register for Updates
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
11/27/2023
Locations: The Belinga Clinic, Fort Smith, Arkansas +90 locations
Conditions: Migraine
Register for Updates
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Clinical Research Institute, Los Angeles, California +76 locations
Conditions: Migraine
Register for Updates
Aimovig Pregnancy Exposure Registry
NCT06150781
Recruiting
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Gender:
Female
Ages:
Between 18 years and 99 years
Trial Updated:
11/21/2023
Locations: IQVIA Virtual Site, Durham, North Carolina
Conditions: Migraine
Register for Updates
GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
NCT04100135
Recruiting
Multi-center, prospective, randomized, placebo- and sham-controlled study to evaluate the GORE® CARDIOFORM Septal Occluder for migraine headache relief
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
11/17/2023
Locations: Mayo Clinic Arizona, Phoenix, Arizona +14 locations
Conditions: Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
Register for Updates
A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention.
NCT05940870
Recruiting
Nerivio is a remote electrical neuromodulation (REN) device that is FDA-cleared for migraine prevention (as well as for acute treatment of migraine), in individuals 12 and older. The study is a post-marketing, observational, prospective, real-world evidence study assessing the safety, efficacy, and health economics outcomes of Nerivio for migraine prevention in a real-world environment. The study population is naïve Nerivio users, aged 12 and up, who were prescribed Nerivio by their healthcare p... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
11/15/2023
Locations: Theranica Inc USA, Bridgewater, New Jersey
Conditions: Migraine
Register for Updates
Treatment for Migraine and Mood RCT
NCT05576467
Recruiting
The researchers propose a three-arm pilot study of Mindfulness-Based Cognitive Therapy (MBCT) delivered via telephone (Telephone), video (Video) or online education modules (Online).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Migraine, Depressive Symptoms
Register for Updates
Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine
NCT03836040
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric subjects with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
11/15/2023
Locations: Paradigm Clinical Research - La Mesa, La Mesa, California +105 locations
Conditions: Migraine
Register for Updates